Logo

Repherans noktası

Ocak 2022 yayın taraması

Tedaviye özel yayınlar

Epoprostenol

PH

1. Ohsumi A et al. New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension. Gen Thorac Cardiovasc Surg. 2022 [Epub]. PMID:34978021.

Masitentan

PH

2. Jariwala P et al. The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up. Lung India. 2022;39(1):12-5. PMID:34975047.

3. Pervaiz A, Saydain G. Pulmonary hypertension in India: Need for organized approach. (Editorial) Lung India. 2022;39(1):3-4. PMID:34975045.

PAH

4. Chen Y et al. The transition from ambrisentan to macitentan in patients with pulmonary arterial hypertension: A real-word prospective study. Front Pharmacol. 2021;12:811700. PMID:35095523.

Seleksipag

PH

5. Maeder MT. Selexipag and the pulmonary hypertension continuum. (Editorial) Eur J Heart Fail. 2022;24(1):215-8. PMID:34816552.

Genel PH tedavisi

PH

6. Barnett CF, O'Brien C, De Marco T. Critical care management of the patient with pulmonary hypertension. Eur Heart J Acute Cardiovasc Care. 2022;11(1):77-83. PMID:34966914.

PAH

7. Manzi G et al. Computational simulator models and invasive hemodynamic monitoring as tools for precision medicine in pulmonary arterial hypertension. J Clin Med. 2021;11(1). PMID:35011825.

8. Morland K et al. Reasons for refusing parenteral therapy: A qualitative study of patients with pulmonary arterial hypertension. Pulm Circ. 2021;11(4). PMID:35024138.

9. Ewert R et al. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. (Review) Expert Rev Respir Med. 2022;16(1):57-66. PMID:34846985.

10. Hu L et al. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition. (Review) Drug Discov Today. 2022 [Epub]. PMID:35104622.

KTEPH

11. Sedhom R et al. Use of direct oral anticoagulants in chronic thromboembolic pulmonary hypertension: A systematic review. (Review) J Thromb Thrombolysis. 2022;53(1):51-7. PMID:34132973.

Kombinasyon tedavisi

PAH

12. Hatano M et al. Positive predictors for response to ambrisentan combination therapy in pulmonary arterial hypertension. Int Heart J. 2022;63(1):99-105. PMID:35095084.

13. Weatherald J et al. Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial. J Heart Lung Transplant. 2022 [Epub]. PMID:35090807.

Non-farmakolojik

PH

14. Hwalek A, Rosenheck JP, Whitson BA. Lung transplantation for pulmonary hypertension. (Review) J Thorac Dis. 2021;13(11):6708-16. PMID:34992846.

15. Murray AW et al. Anesthetic considerations in lung transplantation: Past, present and future. (Review) J Thorac Dis. 2021;13(11):6550-63. PMID:34992834.

PAH

16. Anderson JH et al. Transcatheter nonductal reverse Potts shunt creation in pulmonary arterial hypertension. Circ Cardiovasc Interv. 2022;15(1):e011315. PMID:34930014.

17. Doi A et al. Surgical management of giant pulmonary artery aneurysms in patients with severe pulmonary arterial hypertension. (Review) J Card Surg. 2022 [Epub]. PMID:35040512.

Sol kalp hastalığına bağlı PH (Grup 2)

18. Gazengel P et al. Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. Eur Respir J. 2022;59(1). PMID:34737221.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

19. RoyChoudhury A, Rahman A, Harhay MO. Survival by lung-transplantation preference in interstitial lung disease patients with severe pulmonary hypertension and high lung allocation score. Lung. 2022 [Epub]. PMID:35064335.

KTEPH

20. Darocha S et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: A multicentre registry. EuroIntervention. 2022;17(13):1104-11. PMID:34219663.

21. Oka T et al. Appropriate balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension improves right ventricular ejection fraction via lung perfusion scan. Int Heart J. 2022;63(1):91-8. PMID:35095083.

22. Takigami M et al. The effectiveness of scoring balloon angioplasty in the treatment of chronic thromboembolic pulmonary hypertension. PLoS One. 2022;17(2):e0263244 [Epub]. PMID:35113935.

23. Wiedenroth CB et al. Does age matter? Pulmonary endarterectomy in the elderly patient with CTEPH. Thorac Cardiovasc Surg. 2022 [Epub]. PMID:35038757.

Etiyolojiye özel yayınlar

Pulmoner hipertansiyon

Genel PH

24. Araruna LVM et al. Interplay between thyroid hormone status and pulmonary hypertension in Graves' disease: Relevance of the assessment in thyrotoxic and euthyroid patients. Front Endocrinol (Lausanne). 2021;12:780397. PMID:35069439.

25. Cao R et al. Effect of Xuezhikang therapy on expression of pulmonary hypertension related miR-638 in patients with low HDL-C levels. Front Pharmacol. 2021;12:764046. PMID:34987392.

26. Chiba Y et al. Determinants of altered left ventricular suction in pre-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2022 [Epub]. PMID:35019957.

27. D'Alto M et al. Echocardiographic probability of pulmonary hypertension: A validation study. Eur Respir J. 2022 [Epub]. PMID:34996833.

28. Diamanti E et al. Carbon monoxide diffusion capacity as a severity marker in pulmonary hypertension. J Clin Med. 2021;11(1). PMID:35011871.

29. Farooq O et al. Pulmonary hypertension as a predictor of early outcomes of mitral valve replacement: A study in rheumatic heart disease patients. Cureus. 2021;13(12):e20070. PMID:35003943.

30. Jaroszyński A et al. The value of ventricular gradient for predicting pulmonary hypertension and mortality in hemodialysis patients. Sci Rep. 2022;12(1):456. PMID:35013477.

31. Jentzer JC et al. Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit. Eur Heart J Acute Cardiovasc Care. 2022 [Epub]. PMID:35064269.

32. Kubota K et al. Relationship between dasatinib-induced pulmonary hypertension and drug dose. Intern Med. 2022 [Epub]. PMID:35022343.

33. Lammi MR et al. Jugular venous ultrasound predicts outcomes in pulmonary hypertension outpatients. Eur Respir J. 2022;59(1). PMID:34887321.

34. LaPatra T et al. Remote six-minute walk testing in patients with pulmonary hypertension: A pilot study. Am J Respir Crit Care Med. 2022 [Epub]. PMID:35015981.

36. Melzig C et al. Utility of automated cardiac chamber volumetry by non-gated CT pulmonary angiography for detection of pulmonary hypertension using the 2018 updated hemodynamic definition. AJR Am J Roentgenol. 2022 [Epub]. PMID:35080457.

36. Radvansky BM et al. Pulmonary hypertension in pregnancy: A positive outcome with a multidisciplinary team and individualized treatment plan. J Cardiothorac Vasc Anesth. 2022 [Epub]. PMID:35105488.

37. Saunders H et al. Comparing diagnosis and treatment of pulmonary hypertension patients at a pulmonary hypertension center versus community centers. Diseases. 2022;10(1). PMID:35076491.

38. Schneider M et al. Severe tricuspid regurgitation: Prognostic role of right heart remodelling and pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2022;23(2):246-54. PMID:33615333.

39. Vos JL et al. Cardiovascular magnetic resonance-derived left ventricular intraventricular pressure gradients among patients with precapillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2022 [Epub]. PMID:34993533.

40. Xu C et al. Use of small pulmonary vascular alterations to identify different types of pulmonary hypertension: A quantitative computed tomography analysis. J Xray Sci Technol. 2022;30(1):185-93. PMID:34864713.

41. Zhang L et al. RNA modification signature of peripheral blood as a potential diagnostic marker for pulmonary hypertension. Hypertension. 2022:12118724 [Epub]. PMID:35012324.

42. Bush DS, Ivy DD. Pulmonary hypertension in the population with Down Syndrome. (Review) Cardiol Ther. 2022. PMID:35037192.

43. Farrell Cet al. A clinical approach to multimodality imaging in pulmonary hypertension. (Review) Front Cardiovasc Med. 2021;8:794706. PMID:35118142.

44. Kovacs G, Olschewski H. The definition of pulmonary hypertension: History, practical implications and current controversies. (Review) Breathe (Sheff). 2021;17(3):210076. PMID:35035548.

45. Luongo F et al. Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension. (Review) Heart Fail Rev. 2022 [Epub]. PMID:35098382.

Pediatrik PH

46. Critser PJ et al. Recovery of right ventricular function after bilateral lung transplantation for pediatric pulmonary hypertension. Pediatr Transplant. 2022:e14236 [Epub]. PMID:35098627.

47. Kong F, Sun YL, Yuan B. Prevalence of pulmonary hypertension in children with adenoid or adenotonsillar hypertrophy: A meta-analysis. Int J Pediatr Otorhinolaryngol. 2022;153. PMID:34972075.

48. Rahayuningsih SE et al. Low serum 25-hydroxyvitamin D (vitamin D) level among children with ventricular septal defect: How big is the risk for pulmonary hypertension? Cardiol Young. 2022:1-5 [Epub]. PMID:35067256.

49. Rosenzweig EB et al. Cardiac catheterization and hemodynamics in a multicenter cohort of children with pulmonary hypertension. Ann Am Thorac Soc. 2022 [Epub]. PMID:35049414.

50. Evers PD, Scottoline B, Armsby LB. Acute right ventricular failure associated with pulmonary hypertension in pediatrics: Understanding the hemodynamic profiles. (Review) J Perinatol. 2022;42(1):139-42. PMID:34663899.

Pulmoner arteriyel hipertansiyon (Grup 1)

Genel PAH

51. Cheng S, Li VW, Cheung YF. Systolic and diastolic functional reserve of the subpulmonary and systemic right ventricles as assessed by pharmacologic and exercise stress: A systematic review. Echocardiography. 2022;39(2):310-29. PMID:34997638.

52. Coskun FY, Taysı S, Kayıkçıoğlu M. Can serum 8-hydroxy-2'-deoxyguanosine levels reflect the severity of pulmonary arterial hypertension? Rev Assoc Med Bras (1992). 2021;67(10):1437-42. PMID:35018972.

53. Ding L et al. Association between the coronary sinus ostial size and atrioventricular nodal reentrant tachycardia in patients with pulmonary arterial hypertension. Front Physiol. 2021;12. PMID:35126179.

54. He W et al. Impact of pulmonary arterial hypertension on systemic inflammation, cardiac injury and hemodynamics in sepsis: A retrospective study from MIMIC-III. Am J Med Sci. 2022. PMID:35038420.

55. Rhodes CJ et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2022. PMID:35081018.

56. Shu T et al. Multidisciplinary team managements and clinical outcomes in patients with pulmonary arterial hypertension during the perinatal period. Front Cardiovasc Med. 2021;8. PMID:34977200.

57. Vraka A, Yerly P, Aubert JD. Comparison of risk stratification scores in pulmonary arterial hypertension: A monocentric retrospective study at Lausanne University Hospital. Respiration. 2022:1-12. PMID:35045412.

58. Chen CY et al. Pulmonary arterial hypertension in the elderly population. (Review) J Chin Med Assoc. 2022;85(1):18-23. PMID:34759211.

59. Predescu DN, Mokhlesi B, Predescu SA. The impact of sex chromosomes in the sexual dimorphism of pulmonary arterial hypertension. (Review) Am J Pathol. 2022. PMID:35114193.

60. Tobal R et al. Vascular remodeling in pulmonary arterial hypertension: The potential involvement of innate and adaptive immunity. (Review) Front Med (Lausanne). 2021;8:806899. PMID:35004784.

61. Schwiening M et al. Different cytokine patterns in BMPR2-mutation positive patients and pulmonary arterial hypertension patients without mutations and their influence on survival. (Letter) Chest. 2022. PMID:35063447.

İdiyopatik PAH

62. Chen J et al. Differential serum lipid distribution in IPAH and CHD-PAH patients. Respir Med. 2022;191:106711. PMID:34890866.

63. He W et al. Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension. Physiol Rep. 2022;10(1):e15101. PMID:34981661.

64. Wang Q et al. Prognostic value of follicle-stimulating hormone levels in predicting survival in men with idiopathic pulmonary arterial hypertension. Am J Mens Health. 2022;16(1). PMID:34979822.

İlişkili PAH

65. Kaemmerer AS et al. Medical treatment of pulmonary hypertension in adults with congenital heart disease: Updated and extended results from the International COMPERA-CHD Registry. Cardiovasc Diagn Ther. 2021;11(6):1255-68. PMID:35070795.

66. Kong K et al. A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis. J Scleroderma Relat Disord. 2021;6(3):242-6. PMID:35005243.

67. Liu Y et al. Risk factors associated with pulmonary arterial hypertension among HIV-infected adults: A meta-analysis and systematic review. AIDS Rev. 2022. PMID:35025858.

68. Türker F et al. Evaluation of predisposing metabolic risk factors for portopulmonary hypertension in patients with NASH cirrhosis. Int J Gen Med. 2022;15:859-65. PMID:35115812.

69. Ye H et al. The prognostic value of sST2 in connective tissue disease patients with pulmonary hypertension. Rheumatology (Oxford). 2022. PMID:35094054.

70. Yuan YP et al. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: A retrospective study. Clin Rheumatol. 2022 [Epub]. PMID:35099674.

71. Zhang S et al. Prevalence of sarcoidosis-associated pulmonary hypertension: A systematic review and meta-analysis. Front Cardiovasc Med. 2021;8. PMID:35111830.

Sol kalp hastalığına bağlı PH (Grup 2)

72. Ahmed S, Ahmed A, Rådegran G. Data on plasma tumour and metabolism related proteins' potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension. Data Brief. 2022;40:107747. PMID:35024391.

73. Bartolo MA et al. Numerical predictions of shear stress and cyclic stretch in pulmonary hypertension due to left heart failure. Biomech Model Mechanobiol. 2022;21(1):363-81. PMID:35037114.

74. Cajigas HR et al. The impact of pulmonary hypertension on outcomes of transcatheter mitral valve replacement in mitral annular calcification. Catheter Cardiovasc Interv. 2022 [Epub]. PMID:35019204.

75. Deferm S et al. Impact of pulmonary hypertension on outcomes in patients with mitral annular calcium and associated mitral valve dysfunction. Am J Cardiol. 2022. PMID:34991846.

76. Maeder MT et al. Wedge pressure vs left ventricular end-diastolic pressure for pulmonary hypertension classification and prognostication in severe aortic stenosis. CJC Open. 2021;3(12):1428-37. PMID:34993454.

77. Zhou Y et al. Echocardiographic estimated pulmonary systolic pressure and outcome after noncardiac-obstetrics surgery in postcapillary pulmonary hypertensive patients. Am J Cardiol. 2022 [Epub]. PMID:35065802.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

78. Guo HJ et al. Plasma brain natriuretic peptide, platelet parameters, and cardiopulmonary function in chronic obstructive pulmonary disease. World J Clin Cases. 2021;9(36):11165-72. PMID:35071547.

79. Guo W et al. Clinical value of FeNO for pulmonary hypertension diagnosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Emerg Med Int. 2022. PMID:35127179.

80. Kovacs G et al. Severe pulmonary hypertension in COPD - impact on survival and diagnostic approach. Chest. 2022. PMID:35092746.

81. Oh S et al. Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease. Medicine (Baltimore). 2022;101(3). PMID:35060541.

82. Simonson JL et al. Sleep architecture in patients with interstitial lung disease with and without pulmonary hypertension. Sleep Breath. 2022. PMID:34993759.

KTEPH ve diğer pulmoner arter obstrüksiyonları (Grup 4)

83. Kamada H et al. Quantification of vortex flow in pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension. Eur J Radiol. 2022;148:110142. PMID:35066341.

84. Manz XD et al. Epigenetic modification of the VWF promotor drives platelet aggregation on the pulmonary endothelium in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2022. PMID:35081007.

85. Osman B et al. Initiating a chronic thromboembolic pulmonary hypertension and pulmonary endarterectomy program based on a single center experience in Lebanon. Semin Cardiothorac Vasc Anesth. 2022. PMID:35067123.

86. Tan TH, Ismail R. Utility of lung perfusion SPECT/CT in detection of pulmonary thromboembolic disease: Outcome analysis. Nucl Med Mol Imaging. 2022:1-8. PMID:35013684.

87. Türer Cabbar A et al. Evaluation of asymmetric dimethylarginine levels in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy. Heart Lung Circ. 2022;31(1):110-8. PMID:34130918.

88. Cannon JE, Jenkins DP, Hoole SP. Chronic thromboembolic pulmonary hypertension: A review of risk factors, management and current challenges. (Review) Expert Rev Cardiovasc Ther. 2022:1-9. PMID:35081846.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

89. Nagaraju SP et al. Risk factors of pulmonary hypertension in patients on hemodialysis: A single center study. Int J Nephrol Renovasc Dis. 2021;14:487-94. PMID:34992427.

90. Pinto VM et al. Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood. 2022. PMID:34986266.

91. Carrillo-Rocha DL et al. Review of the myelodysplastic syndrome as a cause of group V pulmonary arterial hypertension: An orphan disease in an orphan pulmonary hypertension group. (Review) Curr Probl Cardiol. 2022:101110. PMID:35007638.

SSc-DU

92. Giuggioli D et al. Infections of scleroderma digital ulcers: A single center cohort retrospective study. Dermatol Reports. 2021;13(3):9075. PMID:35003566.

93. Shiri K et al. G- CSF treatment for refractory digital ulcers in systemic sclerosis. (Letter) Joint Bone Spine. 2022:105348.

PMID:35066186.

Hazırlama tarihi: Mart 2022 

CP-299866